Daily Ards Research Analysis
Three papers advance understanding and management of ARDS. A large retrospective cohort using the 2023 global ARDS definition shows a 4.4% incidence during haematopoietic reconstitution after allo-HSCT and an eightfold increase in 1-year mortality, with identifiable risk factors. Complementing this, patient proteomics suggests early IVIG modulates coagulation and complement pathways in COVID-19, while a targeted review highlights exosomal miRNAs as intercellular regulators and therapeutic candid
Summary
Three papers advance understanding and management of ARDS. A large retrospective cohort using the 2023 global ARDS definition shows a 4.4% incidence during haematopoietic reconstitution after allo-HSCT and an eightfold increase in 1-year mortality, with identifiable risk factors. Complementing this, patient proteomics suggests early IVIG modulates coagulation and complement pathways in COVID-19, while a targeted review highlights exosomal miRNAs as intercellular regulators and therapeutic candidates in ALI/ARDS.
Research Themes
- Transplant-related ARDS risk and prognosis
- Immune–coagulation–complement crosstalk and IVIG timing in viral ARDS
- Exosomal miRNAs as intercellular regulators and therapeutic vectors in ALI/ARDS
Selected Articles
1. ARDS during haematopoietic reconstruction after allogeneic haematopoietic stem cell transplantation (allo-HSCT) in non-child patients: based on the new global definition.
In 1024 allo-HSCT recipients, ARDS (per 2023 global definition) occurred in 4.4% during haematopoietic reconstitution, typically around day 9, and conferred an eightfold higher 1-year mortality. Independent risk factors included longer disease-to-transplant interval, more prior HSCTs, and elevated admission RDW; most ARDS cases were managed with high-flow nasal oxygen.
Impact: Provides the first incidence and risk-factor profile of ARDS during haematopoietic reconstitution using the 2023 global definition, with strong prognostic implications for post-transplant care.
Clinical Implications: Transplant programs should implement early ARDS surveillance during haematopoietic reconstitution, particularly in patients with prolonged disease-to-transplant intervals, multiple prior HSCTs, or elevated RDW, and consider proactive oxygenation and ICU triage protocols.
Key Findings
- ARDS incidence during haematopoietic reconstitution was 4.4% (45/1024), with median onset at day 9 post-transplant.
- ARDS was associated with markedly increased 1-year mortality (HR 7.99, 95% CI 4.13–15.44).
- Independent risk factors: longer disease onset-to-transplant interval (OR 1.01), more prior HSCTs (OR 1.82), higher admission RDW (OR 1.12).
- Among ARDS cases, 29/45 were managed with high-flow nasal oxygen alone.
Methodological Strengths
- Large single-cohort (n=1024) with multivariable modeling of risk factors and outcomes
- Use of the 2023 global ARDS definition, enhancing diagnostic consistency
Limitations
- Retrospective, single-region design with potential unmeasured confounding
- No external validation or mechanistic investigations to explain observed associations
Future Directions: Prospective, multicenter validation of risk factors; development of a prediction tool for ARDS during reconstitution; interventional studies testing early detection and prevention strategies.
BACKGROUND: Haematopoietic reconstitution is marked by immunosuppression and pancytopenia, representing the initial high-risk period following allogeneic haematopoietic stem cell transplantation (allo-HSCT). However, little is known about the occurrence of acute respiratory distress syndrome (ARDS) during haematopoietic reconstitution. METHODS: This retrospective cohort study included 1024 patients who underwent allo-HSCT in Suzhou from 2016 to 2019. Clinical data and follow-up information were collected from medical records. ARDS was defined according to the new global definition established in 2023. The primary outcomes were the incidence of ARDS during haematopoietic reconstitution after allo-HSCT and 1 year post-transplantation mortality. RESULTS: Among the 1024 patients, 58 (5.6%) died within 1 year after HSCT. ARDS during haematopoietic reconstitution occurred in 45 patients (4.4%), of whom 29 were treated with high-flow nasal oxygen only. The median onset of ARDS was 9.0 days post-transplantation. Patients who developed ARDS had a significantly higher risk of 1-year mortality after HSCT (HR 7.99, 95% CI 4.13 to 15.44). Independent risk factors for ARDS during haematopoietic reconstitution included longer intervals between disease onset and transplantation (OR 1.01, 95% CI 1.00 to 1.02), a greater number of previous HSCTs (OR 1.82, 95% CI 1.04 to 3.19), and higher red cell distribution width at admission (OR 1.12, 95% CI 1.02 to 1.22). CONCLUSIONS: According to the new 2023 global definition, ARDS during haematopoietic reconstitution is independently associated with increased 1-year mortality after allo-HSCT. Early identification of ARDS during this period is particularly important, and recognising its risk factors may aid in timely diagnosis and intervention.
2. Treatment with intravenous immunoglobulin modulates coagulation- and complement-related pathways in COVID-19 patients.
This first-in-patient proteomic study indicates early IVIG in COVID-19 aligns with faster clinical improvement and modulation of coagulation and complement signatures, including KNG1, FGA, F13B, CPB2 (coagulation) and C1RL, C8G, CFD (complement). Findings support immune–coagulation crosstalk as a potential IVIG mechanism of action.
Impact: Provides mechanistic, patient-derived evidence that IVIG modulates coagulation/complement pathways, informing timing and biomarker-guided use in severe viral pneumonia that often overlaps ARDS.
Clinical Implications: If validated, early IVIG could be targeted to patients with hypercoagulable/complement-activated phenotypes; monitoring coagulation and complement proteins may guide selection and timing.
Key Findings
- Early IVIG administration during hospitalization associated with faster clinical improvement in COVID-19 patients.
- Proteomics showed elevated inflammatory, coagulation, and complement proteins in COVID-19 serum.
- IVIG modulated coagulation proteins (KNG1, ACTB, FGA, F13B, CPB2) and complement proteins (C1RL, C8G, CFD).
- Early timing appears critical to optimize responsiveness to IVIG.
Methodological Strengths
- First proteomic analysis of IVIG-treated COVID-19 patients integrating molecular and clinical outcomes
- Targets biologically plausible pathways (coagulation/complement) with named protein changes
Limitations
- Sample size and exact design details not specified; likely small, observational, and non-randomized
- Potential confounding by indication and heterogeneity of standard care; limited generalizability
Future Directions: Conduct biomarker-stratified, time-to-treatment randomized trials testing IVIG in patients with hypercoagulable/complement-activated phenotypes; validate protein signatures as predictive biomarkers.
INTRODUCTION: Intravenous immunoglobulin (IVIG) is a therapy that uses pooled immunoglobulins from thousands of different donors. While it is primarily used to treat immunodeficiency and autoimmune diseases due to its immunomodulatory properties, IVIG has also been used as an off-label therapy for respiratory infections, including COVID-19. Clinical data regarding the efficacy of IVIG for COVID-19 has been controversial, and although some smaller studies have shown beneficial effects, others including a large randomized trial found no significant clinical impact but noted detrimental secondary effects. METHODS: We describe the first proteomic analysis from the plasma of COVID-19 patients treated with IVIG, as well as clinical outcomes. RESULTS: Patients that received IVIG early upon hospitalization have faster clinical improvement. Proteomic analysis showed that serum from patients with COVID-19 has increased levels of proteins associated with inflammatory responses, activation of coagulation and complement pathways, and dysregulation of lipid metabolism. IVIG therapy significantly impacted pathways related to coagulation. Given known crosstalk between coagulation and complement pathways, we also analyzed complement-related proteins. Overall, treatment with IVIG appeared to modulate coagulation (KNG1, ACTB, FGA, F13B, and CPB2) and complement (C1RL, C8G and CFD) related proteins. DISCUSSION: Our data is supported by similar findings observed in disease states other than COVID-19, where IVIG can impact coagulation and complement proteins. However, early administration seems to be critical determinants to optimize responsiveness to IVIG therapy in COVID-19.
3. [Research advances of exosomal micrornas in regulating the pathogenesis of acute lung injury/acute respiratory distress syndrome].
This narrative review synthesizes how exosomal miRNAs regulate key ALI/ARDS processes across alveolar epithelial cells, endothelium, macrophages, and neutrophils (e.g., autophagy, pyroptosis, apoptosis, polarization), and outlines engineering advances that enhance therapeutic delivery and stability.
Impact: By consolidating mechanistic roles of exosomal miRNAs across cell types and highlighting engineering solutions, it charts a translational path toward RNA-based therapeutics for ALI/ARDS.
Clinical Implications: Although primarily preclinical, exosomal miRNA signatures may inform patient phenotyping and pave the way for targeted extracellular vesicle therapies once safety and delivery hurdles are addressed.
Key Findings
- Exosomal miRNAs mediate intercellular communication affecting autophagy, pyroptosis, apoptosis, proliferation, and inflammatory signaling in ALI/ARDS.
- They regulate macrophage polarization and neutrophil activation, influencing disease progression bidirectionally.
- Engineering advances improve exosomal miRNA delivery and therapeutic potential beyond natural vesicles.
- Multiple lung cell types (epithelial, endothelial) and immune cells (macrophages, neutrophils) are key targets of exosomal miRNAs.
Methodological Strengths
- Integrates mechanistic evidence across multiple cell types and pathways relevant to ALI/ARDS
- Highlights bioengineering innovations that address delivery and stability limitations
Limitations
- Narrative review without PRISMA methodology or quantitative synthesis
- Evidence base largely preclinical with heterogeneity in exosome isolation and characterization
Future Directions: Standardize extracellular vesicle characterization, validate miRNA cargo in vivo across models, and initiate early-phase trials of engineered exosomal miRNA therapeutics for ALI/ARDS.
Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a severe critical condition marked by rapid progression and high fatality. It results from direct/indirect lung-related or systemic triggers, leading to widespread injury of lung epithelial and endothelial cells. Its pathogenesis involves uncontrolled inflammation and breakdown of the lung's blood-air barrier due to leaky blood vessels and epithelial damage. Current management of ALI/ARDS remains primarily supportive, offering symptomatic relief but limited improvement in prognosis, necessitating deeper exploration of upstream pathogenic mechanisms to identify safer and more effective therapies. Exosomal microRNAs (miRNA), small extracellular vesicles (40-150 nm) containing non-coding single-stranded RNAs, regulate post-transcriptional cellular processes and participate in ALI/ARDS pathophysiology. Studies reveal that exosomes transport proteins, nucleic acids, and miRNAs to recipient cells, mediating intercellular communication. In ALI/ARDS models, exosomal miRNAs delivered to alveolar epithelial cells, endothelial cells, macrophages, and neutrophils critically modulate autophagy, pyroptosis, apoptosis, proliferation, inflammatory signaling, macrophage polarization, and neutrophil activation, either exacerbating or alleviating disease progression. Recent advances in engineering techniques have enhanced the therapeutic potential of exosomal miRNAs by overcoming limitations of natural exosomes. This review focuses on exosomal miRNA-mediated regulation of ALI/ARDS pathogenesis across key cell types, providing insights for novel therapeutic strategies.